• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease
CONCLUSIONS: There is currently insufficient evidence to determine the effectiveness of ACEi or ARB in patients with stage 1 to 3 CKD who do not have DM. The available evidence is overall of very low certainty and high risk of bias. We have identified an area of large uncertainty for a group of patients who account for most of those diagnosed as having CKD.PMID:37466151 | DOI:10.1002/14651858.CD007751.pub3
Source: Cochrane Database of Systematic Reviews - July 19, 2023 Category: General Medicine Authors: Tess E Cooper Claris Teng David J Tunnicliffe Brydee A Cashmore Giovanni Fm Strippoli Source Type: research

Pattern of antihypertensive therapy among diabetic hyperten- sive patients in zewditu memorial hospital, addis ababa.
CONCLUSION: The pattern of antihypertensive drug therapy in our patients was consistent with the current treatment guidelines. However, the majority of diabetic-hypertensive patients did not reach target blood pressure. PMID: 27476227 [PubMed - in process]
Source: Ethiopian Medical Journal - August 3, 2016 Category: African Health Tags: Ethiop Med J Source Type: research

Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study Clinical Trial
In the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study, 4.8 years’ losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke. However, there was no difference in myocardial infarction (MI), possibly related to greater reduction in myocardial oxygen demand by atenolol-based treatment. Myocardial oxygen demand was assessed indirectly by the left ventricular massxwall stressxheart rate (triple product) in 905 LIFE participants. The triple product was included as time-varying covariate...
Source: Hypertension - October 7, 2015 Category: Cardiology Authors: Devereux, R. B., Bang, C. N., Roman, M. J., Palmieri, V., Boman, K., Gerdts, E., Nieminen, M. S., Papademetriou, V., Wachtell, K., Hille, D. A., Dahlof, B. Tags: Hypertrophy, Other etiology Clinical Trial Source Type: research

Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients With Left Ventricular Hypertrophy Original Articles
Conclusions— Development of new-onset AF identifies hypertensive patients at increased risk of SCD. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00338260.
Source: Circulation: Arrhythmia and Electrophysiology - April 16, 2013 Category: Cardiology Authors: Okin, P. M., Bang, C. N., Wachtell, K., Hille, D. A., Kjeldsen, S. E., Dahlof, B., Devereux, R. B. Tags: Clinical Studies, Arrhythmias, clinical electrophysiology, drugs, Epidemiology Original Articles Source Type: research